Aimmune’s peanut allergy drug hits PhIII trials
admin 21st February 2018 Uncategorised 0A Phase III trial assessing Aimmune Therapeutics’ experimental peanut allergy drug AR101 has hit its primary targets.
More: Aimmune’s peanut allergy drug hits PhIII trials
Source: News